Please check your internet connection and try again.
# IV Dexamethasone
## Overview
Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It exerts profound anti-inflammatory and immunosuppressive effects through the modulation of gene expression.
## Primary Indications
* Cerebral edema (associated with brain tumors, neurosurgery, or abscesses).
* Anti-emesis (chemotherapy-induced nausea and vomiting).
* Acute airway edema (e.g., croup/stridor).
* Acute exacerbations of asthma or COPD.
* Bacterial meningitis (adjunctive therapy).
* Severe COVID-19 (requiring oxygen therapy).
## Adult Dosing
* **Cerebral Edema:** Initial 10 mg IV push, followed by 4 mg IM/IV every 6 hours.
* **Anti-emesis:** 8–20 mg IV as a single dose before chemotherapy.
* **Anti-inflammatory/Immunosuppressive:** 0.75–9 mg daily in divided doses, depending on severity.
* **COVID-19:** 6 mg IV daily for up to 10 days.
## Pediatric Dosing
* **Croup:** 0.6 mg/kg (max 10 mg) as a single dose.
* **Bacterial Meningitis:** 0.15 mg/kg IV every 6 hours for 4 days (ideally given 10–20 minutes before or concurrent with first antibiotic dose).
* **Asthma:** 0.3–0.6 mg/kg IV as a single dose.
* **Anti-emesis:** 0.25–0.5 mg/kg (max 10–20 mg) per dose.
## Dose Adjustments
* **Hepatic Impairment:** Clearance may be decreased; use with caution and monitor for increased adverse effects.
* **Renal Impairment:** Generally no adjustment required.
* **Geriatrics:** Use the lowest effective dose to minimize risk of osteoporosis, hyperglycemia, and neuropsychiatric effects.
## Contraindications
* Systemic fungal infections.
* Hypersensitivity to dexamethasone or any component of the formulation.
* Use of live or attenuated vaccines in patients receiving immunosuppressive doses.
## Adverse Effects
* **Common:** Hyperglycemia, hypertension, fluid retention, insomnia, dyspepsia, increased appetite.
* **Serious:** Psychosis/mood disorders, peptic ulcer disease, opportunistic infections, adrenal suppression, myopathy, osteonecrosis (long-term).
## Key Drug Interactions
* **CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin):** May decrease dexamethasone levels.
* **CYP3A4 inhibitors (e.g., ketoconazole, ritonavir):** May increase dexamethasone levels.
* **NSAIDs/Aspirin:** Increased risk of gastrointestinal ulceration/bleeding.
* **Antidiabetic agents:** Glucocorticoids antagonize hypoglycemic effects, requiring dose adjustments of insulin or oral agents.
## Monitoring
* Serum glucose (especially in diabetics).
* Blood pressure.
* Signs of infection.
* Psychiatric status (agitation, depression, psychosis).
* Serum electrolytes (if on high-dose or long-term therapy).
## Clinical Pearls
* **Administration:** May be given slow IV push or diluted in NS/D5W and infused.
* **Tapering:** Patients on prolonged courses (typically >1–2 weeks) require a gradual taper to prevent adrenal insufficiency. Single doses or short-term bursts (e.g., for croup) do not require tapering.
* **Hospital Protocol:** Always cross-reference institutional protocols for COVID-19 or meningitis, as adjunct therapies are highly protocol-dependent.
***
*Disclaimer: This information is for educational purposes only. Always consult current institutional guidelines, the product package insert, and clinical decision support tools (e.g., Lexicomp, Micromedex) before prescribing or administering medication.*
